Bipolife: Evaluation of a Serious Game for Patients With Bipolar Disorder Involved in a Psychoeducation Group

Sponsor
University Hospital, Montpellier (Other)
Overall Status
Unknown status
CT.gov ID
NCT02936466
Collaborator
(none)
210
1
2
42
5

Study Details

Study Description

Brief Summary

Bipolar disorder is a condition characterized by succession of episodes- manic, hypomanic, and depressive episodes. Major risks factors of relapses are poor compliance, sleep disorder, and toxics consumption. The aims of psychoeducation programs are to increase compliance and knowledge about bipolar disorder. Serious game are supposed, in bipolar disorder, to strengthen the efficacy of psychoeducation programs. Bipolife® is a serious game which purpose is to help bipolar patients to deal with their conditions, through 3 mains messages : to pursue the treatment, to have daily routine and to request the psychiatrist in case of relapse.

This is a multicentric randomized controlled study with two harms parallels. After a classic psychoeducation group program, patients are randomized in two groups : interventional group and control group with treatment as usual.

The main objective is to evaluate the observance in the two groups. The other objectives are to evaluate daily routine, global functioning, and access to health care. Evaluations are realized at one and four months after inclusion visit. Acceptability and satisfaction about the serious game Bipolife® will be assessed in the interventional group.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Bipolife® group
N/A

Detailed Description

Bipolife® is a serious game for bipolar patients, developed by Astra Zeneca laboratory in collaboration with a french company named Ubisoft. The aim of this interactive tool is to help patient to have a better understanding of their condition and to identify their daily routine which can impact on it.

Three visits :

At the inclusion visit (V0), on the 15days following the end of the psychoeducation group, the investigator evaluate mood, habits, daily routine, and verify inclusion criteria of the participants, in particular euthymic status. The participants are randomized by bloc in each center, in two groups : interventional group (Bipolife®) and control group.

Instructions on interventional group are to periodically connect to BIPOLIFE until next visit.

On the first visit, one month later (V1) and on the second visit, four months later (V2), the investigator evaluate compliance, routine habits and mood.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
210 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Evaluation of a Serious Game for Patients With Bipolar Disorder Involved in a Psychoeducation Group
Study Start Date :
Dec 1, 2014
Anticipated Primary Completion Date :
Jun 1, 2018
Anticipated Study Completion Date :
Jun 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Interventional group

Bipolife group

Behavioral: Bipolife® group
The participant is proposed to play to the serious game Bipolife® with following instructions : At least one connection per week during 4 weeks Connection time is free On add on of usual treatment After the 4 weeks and the first visit (V1), the participant can continue to participate to the serious game as much as he wishes, without any specific instructions. After connecting to the site www.bipolar.ubi.com, the participant is proposed to create his avatar and conduct him on his house. He realizes different kind of daily actions (like sleeping, sport activity, cooking) ; every action lead to win or to loose "energy" and "mood" points. The final aim is to stabilize the avatar's mood. Thanks to this experience, the participant can learn to distinguish positive and negative actions impacting on his condition.

No Intervention: Control group

No specific intervention, treatment as usual

Outcome Measures

Primary Outcome Measures

  1. Compliance rate [At 4 months after the inclusion]

    Evaluation of patient compliance by Medication Adherence Rating Scale (MARS) score.

Secondary Outcome Measures

  1. Evolution of toxic consumption [Between 1 and 4 months after the inclusion]

    evaluation of toxic consumption : patient will be asked about his consumption, and to pass the french scale Cut-down, Annoyed, Guilty, Eye-opener (CAGE- DETA)

  2. Evolution of sleep disturbance [Between 1 and 4 months after the inclusion]

    evaluation of sleep disturbance (by Pittsburgh Sleep Quality Index PSQI)

  3. Evolution of the alimentation [Between 1 and 4 months after the inclusion]

    evaluation of alimentation (patient will be asked about his alimentation)

  4. Global functioning [At 1 and 4 months after the inclusion]

    evaluation of global functioning is realized by the Functioning Assessment Short Test (FAST) scale.

  5. Ability to access health care in emergency description : number of emergency consultation for psychiatric reason [At 1 and 4 months after the inclusion]

    evaluation of the ability to require to health care structures : Patients will be asked about their consultations and hospitalisations during the follow-up

  6. acceptability and satisfaction [At 1 and 4 months after the inclusion]

    only on the "interventional group" : evaluation of the acceptability and satisfaction by a home made acceptability scale.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion criteria:
  • diagnosis of bipolar disorder according to the Diagnostic and Statistical Manual (DSM) IV

  • euthymic status at least since 3 months

  • participation to a psychoeducation group ending on the 15 last days

  • realized at less 50% of the sessions of psychoeducation group

  • free access to a computer with internet connection

  • signed informed consent

Exclusion criteria:
  • decline of participation

  • patient on protective measures (guardianship or trusteeship)

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Montpellier Hospital Montpellier France 34295

Sponsors and Collaborators

  • University Hospital, Montpellier

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Montpellier
ClinicalTrials.gov Identifier:
NCT02936466
Other Study ID Numbers:
  • UF 9238
  • 2013-A01481-44
First Posted:
Oct 18, 2016
Last Update Posted:
Oct 18, 2016
Last Verified:
Jul 1, 2016
Keywords provided by University Hospital, Montpellier
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 18, 2016